

Arianna Calcinotto – Publication list

*equally contributed

1. Bonfiglio F, Brusca A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabbatini E, Salles G, Santambrogio E, Scarfò L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, **Calcinotto A**, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E and Rossi D, *Genetic and phenotypic attributes of splenic marginal zone lymphoma*. *Blood*, 2022. 139(5): p. 732-747.
2. Zorzi M, Guzzinati S, Avossa F, Fedeli U, **Calcinotto A** and Rügge M, *SARS-CoV-2 Infection in Cancer Patients: A Population-Based Study*. *Front Oncol*, 2021. 11: p. 730131.
3. Pernigoni N*, Zagato E*, **Calcinotto A***, Troiani M, Mestre RP, Cali B, Attanasio G, Troisi J, Minini M, Mosole S, Revandkar A, Pasquini E, Elia AR, Bossi D, Rinaldi A, Rescigno P, Flohr P, Hunt J, Neeb A, Buroni L, Guo C, Welte J, Ferrari M, Grioni M, Gauthier J, Gharaibeh RZ, Palmisano A, Lucchini GM, D'Antonio E, Merler S, Bolis M, Grassi F, Esposito A, Bellone M, Briganti A, Rescigno M, Theurillat JP, Jobin C, Gillessen S, de Bono J and Alimonti A, *Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis*. *Science*, 2021. 374(6564): p. 216-224.
4. Mukherjee S, Elia AR and **Calcinotto A**, *Role of myeloid-derived suppressor cells in hormone-dependent cancers*. *Swiss Med Wkly*, 2021. 151: p. w20483.
5. Montopoli M, Zorzi M, Cocetta V, Prayer-Galetti T, Guzzinati S, Bovo E, Rügge M and **Calcinotto A**, *Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy*. *Ann Oncol*, 2021. 32(5): p. 676-677.
6. Grioni M, Brevi A, Cattaneo E, Rovida A, Bordini J, Bertilaccio MTS, Ponzoni M, Casorati G, Dellabona P, Ghia P, Bellone M and **Calcinotto A**, *CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Emu-TCL1 mice through a CD40L-independent mechanism*. *Blood Adv*, 2021. 5(14): p. 2817-2828.
7. Bolis M, Bossi D, Vallergera A, Ceserani V, Cavalli M, Impellizzieri D, Di Rito L, Zoni E, Mosole S, Elia AR, Rinaldi A, Pereira Mestre R, D'Antonio E, Ferrari M, Stoffel F, Jermini F, Gillessen S, Bubendorf L, Schraml P, **Calcinotto A**, Corey E, Moch H, Spahn M, Thalmann G, Kruithof-de Julio M, Rubin MA and Theurillat JP, *Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression*. *Nat Commun*, 2021. 12(1): p. 7033.
8. Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, **Calcinotto A**, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welte J, Gil V, Yuan W, Vljajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Campese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Ruschoff JH, Wild P, Moch H, De Bono J and Alimonti A, *CD40L overexpression drives prostate cancer progression and can be targeted in vivo*. *J Clin Invest*, 2020. 130(5): p. 2435-2450.
9. Di Mitri D, Miranda M, Vasilevska J, **Calcinotto A**, Delaleu N, Revandkar A, Gil V, Boysen G, Losa M, Mosole S, Pasquini E, D'Antuono R, Masetti M, Zagato E, Chiorino G, Ostano P, Rinaldi A,

- Gnetti L, Graupera M, Martins Figueiredo Fonseca AR, Pereira Mestre R, Waugh D, Barry S, De Bono J and Alimonti A, *Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer*. Cell Rep, 2019. 28(8): p. 2156-2168 e5.
10. **Calcinotto A**, Kohli J, Zagato E, Pellegrini L, Demaria M and Alimonti A, *Cellular Senescence: Aging, Cancer, and Injury*. Physiol Rev, 2019. 99(2): p. 1047-1078.
 11. Cortesi F, Delfanti G, Grilli A, **Calcinotto A**, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, Briganti A, Salonia A, De Palma M, Bicciato S, Doglioni C, Bellone M, Casorati G and Dellabona P, *Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression*. Cell Rep, 2018. 22(11): p. 3006-3020.
 12. **Calcinotto A**, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Luciano R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J and Alimonti A, *IL-23 secreted by myeloid cells drives castration-resistant prostate cancer*. Nature, 2018. 559(7714): p. 363-369.
 13. **Calcinotto A***, Brevi A*, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt VM, Sharik ME, Henderson KJ, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell RA, Huber S, Canducci F, Rajkumar VS, Bergsagel PL and Bellone M, *Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression*. Nat Commun, 2018. 9(1): p. 4832.
 14. **Calcinotto A** and Alimonti A, *Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer*. Swiss Med Wkly, 2017. 147: p. w14367.
 15. Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, **Calcinotto A**, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM and Ghobrial IM, *Targeting vasculogenesis to prevent progression in multiple myeloma*. Leukemia, 2016. 30(5): p. 1103-15.
 16. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosioerek HE, **Calcinotto A**, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D and Bergsagel PL, *IAP antagonists induce anti-tumor immunity in multiple myeloma*. Nat Med, 2016. 22(12): p. 1411-1420.
 17. Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, **Calcinotto A**, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F and Corti A, *Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients*. Cancer Res, 2016. 76(7): p. 1781-91.
 18. Jachetti E, Caputo S, Mazzoleni S, Brambillasca CS, Parigi SM, Grioni M, Piras IS, Restuccia U, **Calcinotto A**, Freschi M, Bachi A, Galli R and Bellone M, *Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation*. Cancer Res, 2015. 75(10): p. 2095-108.
 19. **Calcinotto A**, Ponzoni M, Ria R, Grioni M, Cattaneo E, Villa I, Sabrina Bertilaccio MT, Chesi M, Rubinacci A, Tonon G, Bergsagel PL, Vacca A and Bellone M, *Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma*. Oncoimmunology, 2015. 4(6): p. e1008850.
 20. Ricupito A, Grioni M, **Calcinotto A**, Hess Michelini R, Longhi R, Mondino A and Bellone M, *Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings*. Cancer Res, 2013. 73(12): p. 3545-54.
 21. Ricupito A, Grioni M, **Calcinotto A** and Bellone M, *Boosting anticancer vaccines: Too much of a good thing?* Oncoimmunology, 2013. 2(7): p. e25032.

22. Jachetti E, Mazzoleni S, Grioni M, Ricupito A, Brambillasca C, Generoso L, **Calcinotto A**, Freschi M, Mondino A, Galli R and Bellone M, *Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses*. *Oncoimmunology*, 2013. 2(5): p. e24520.
23. Bellone M, **Calcinotto A**, Filipazzi P, De Milito A, Fais S and Rivoltini L, *The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors*. *Oncoimmunology*, 2013. 2(1): p. e22058.
24. Bellone M and **Calcinotto A**, *Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes*. *Front Oncol*, 2013. 3: p. 231.
25. **Calcinotto A**, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A and Bellone M, *Targeting TNF- α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy*. *J Immunol*, 2012. 188(6): p. 2687-94.
26. **Calcinotto A***, Filipazzi P*, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, Huber V, Parmiani G, Generoso L, Santinami M, Borghi M, Fais S, Bellone M* and Rivoltini L*, *Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes*. *Cancer Res*, 2012. 72(11): p. 2746-56.
27. Bellone M, Ceccon M, Grioni M, Jachetti E, **Calcinotto A**, Napolitano A, Freschi M, Casorati G and Dellabona P, *iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells*. *PLoS One*, 2010. 5(1): p. e8646.